Skip to main content

Table 1 Patients’ characteristics of the HPBC and HNBC cohorts, and comparison of clinicopathological features of breast tumors in low and high tATM group

From: Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer

Baseline characteristics

HNBC cohort

HPBC cohort

Full cohort

tATM low

tATM high

tATM low vs high

Full cohort

tATM low

tATM high

tATM low vs high

n = 168 (%)

n = 22 (%)

n = 79 (%)

P value

n = 130 (%)

n = 36 (%)

n = 66 (%)

P value

Age median (min-max)

53 (30–82)

58 (33–80)

51(30–82)

0.145

67 (38–88)

71(41–86)

68 (38–88)

0.408

Tumor size

        

T1/T2 (≤5 cm)

143 (85%)

20 (20%)

67 (66%)

1.00

116 (89%)

27 (26%)

65 (64%)

0.002

T3/T4 (>5 cm)

16 (10%)

2 (2%)

10 (10%)

 

10 (8%)

7 (7%)

1 (1%)

 

Missing

9 (5%)

 

2 (2%)

 

4 (3%)

2 (2%)

  

Grade

        

1

3 (2%)

0 (0%)

0 (0%)

0.295

25 (19%)

6 (6%)

12 (12%)

0.029

2

29 (17%)

5 (5%)

9 (9%)

 

63 (48%)

10 (10%)

38 (37%)

 

3

121 (72%)

17 (17%)

68 (67%)

 

32 (25%)

15(14.5%)

15(14.5%)

 

Missing

15 (9%)

 

2 (2%)

 

10 (8%)

5 (5%)

1 (1%)

 

LVI

        

+

47 (28%)

7 (7%)

27 (27%)

0.621

26 (20%)

7 (7%)

13 (13%)

0.584

-

97 (58%)

15(15%)

43 (42%)

 

76 (58%)

17 (16%)

43 (42%)

 

Missing

24 (14%)

 

9 (9%)

 

28 (22%)

12 (12%)

10 (10%)

 

LN

        

0

97 (58%)

15(15%)

41 (40%)

0.230

67 (51%)

14 (14%)

38 (37%)

0.03

>0

64 (38%)

7 (7%)

37 (37%)

 

49 (38%)

20 (19.5%)

20 (19.5%)

 

Missing

7 (4%)

 

1 (1%)

 

14 (11%)

2 (2%)

8 (8%)

 

Stage

        

I

55 (33%)

4 (4%)

25 (25%)

0.551

40 (31%)

6 (6%)

25 (24%)

0.002

II

81 (48%)

13 (13%)

35 (34%)

 

43 (33%)

13 (13%)

22 (21.5%)

 

III

23 (14%)

4 (4%)

16 (16%)

 

25 (19%)

15 (14.5%)

7 (7%)

 

DCIS and IV

9 (5%)

1 (1%)

3 (3%)

 

3 (2%)

0 (0%)

1 (1%)

 

Missing

NA

   

19 (15%)

2 (2%)

11 (11%)

 

ER/PR status

        

Positive

11 (7%)

0 (0%)

0 (0%)

 

130 (100%)

36 (35%)

66 (65%)

 

Negative

48 (92%)

22 (22%)

79 (78%)

 

NA

   

Missing

2 (1%)

   

NA

   

HER2 status

    

NA

   

Positive

62 (36%)

6 (6%)

33 (33%)

0.22

    

Negative

104 (62%)

16 (16%)

46 (45%)

     

Missing

2 (1%)

       

RT

        

Yes

100 (60%)

11 (11%)

55 (54%)

0.127

70 (54%)

20 (20%)

38 (37%)

0.831

No

68 (40%)

11 (11%)

24 (24%)

 

56 (43%)

15 (15%)

25 (24%)

 

Unknown

NA

   

4 (3%)

1 (1%)

3 (3%)

 

Chemotherapy

        

Anthracycline-based

105 (62%)

11 (11%)

59 (58%)

0.04

    

Anthracycline and taxane-based

11 (7%)

3 (3%)

3 (3%)

     

CMF or 5FU

7 (4%)

0 (0%)

4 (4%)

     

Unknown

3 (2%)

1 (1%)

1 (1%)

 

1 (1%)

   

None

42 (25%)

7 (7%)

12 (12%)

 

129 (99%)

   
  1. One hundred and sixty-eight HNBC and 130 HPBC patients diagnosed with EBC were included in the study. Clinical and histopathological features were summarized and described in numeric numbers and proportions in both cohorts. Sixty-seven cases in the HNBC cohort and 28 cases in the HPBC cohort were excluded for failing to obtain ATM staining due to technical issues. Therefore, a total of 101 cases in the HNBC cohort and 102 cases in the HPBC cohort were dichotomized into high and low ATM groups based on tATM AQUA scores. The cut-point was set at 22% in the HNBC cohort and 38% in the HPBC cohort respectively based on X-tile prediction. Student’s t test was used to compare the continuous variable age between low and high ATM groups. Fisher’s exact test was used to compare the clinicopathological features of breast tumors in high and low ATM groups. HPBC, hormone-positive breast cancer; HNBC, hormone-negative breast cancer; tATM, tumor ATM; LVI, lymphvascular invasion; LN, lymph node status; DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; RT, radiation treatment; CMT, combined modality treatment; 5FU, 5-fluorouracil; EBC, early-stage breast cancer; ATM, ataxia telangiectasia mutated; AQUA, automated quantitative immunofluorescence analysis.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us